Drug Trial Radar · NCT05262556
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
Last checked: Nov 19, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Dec 15, 2022
Primary completion
Oct 27, 2025
Study completion Oct 27, 2025
Sponsor
- Lead sponsor
- Amr Mohamed MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Novatek Pharmaceuticals
- First posted
- Mar 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A pilot study to evaluate the anti-tumor efficacy of this novel combined regimen (NP-101 TQ Formula plus nivolumab and ipilimumab) in the second-line setting for EP-NECA. NP-101 (TQ Formula) (TQ, C10H12O2) is the main bioactive component of the black seed (Nigella sativa, Ranunculaceae family) and has anti-oxidant, anti-angiogenic effects.
Conditions
- Gastroenteropancreatic Neuroendocrine Tumor
- Gastroenteropancreatic Neuroendocrine Neoplasm
- Neuroendocrine Carcinoma
- Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
Interventions
NP-101 (TQ Formula)Drug
Oral, five 600mg tabs daily every three weeks for four cycles (21-day cycle), then maintenance for an additional 12 weeks for a total of six cycles.
Nivolumab (3mg/kg)Drug
Intravenously on Day 1 every three weeks for four cycles (maximum dose 360mg once every 3 weeks), then 240mg maintenance every two weeks for six cycles for a total of six months of treatment.
Ipilimumab (1mg/kg)Drug
Intravenously on day 1 of each (21-day) cycle for a total of four cycles only.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Antitumor activity of NP-101 (TQ Formula) plus nivolumab and ipilimumab in subjects with advanced and/or metastatic EP-NECAs who progressed on first line therapyTime frame: Up to 6 months from the start of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.